Tularemia vaccine development: paralysis or progress?
Open Access
- 1 May 2016
- journal article
- review article
- Published by Taylor & Francis in Vaccine: Development and Therapy
- Vol. 6, 9-23
Abstract
Francisella tularensis (Ft) is a gram-negative intercellular pathogen and category A biothreat agent. However, despite 15 years of strong government investment and intense research focused on the development of a US Food and Drug Administration-approved vaccine against Ft, the primary goal remains elusive. This article reviews research efforts focused on developing an Ft vaccine, as well as a number of important factors, some only recently recognized as such, which can significantly impact the development and evaluation of Ft vaccine efficacy. Finally, an assessment is provided as to whether a US Food and Drug Administration-approved Ft vaccine is likely to be forthcoming and the potential means by which this might be achieved.Keywords
This publication has 149 references indexed in Scilit:
- Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organsVaccine, 2010
- Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: Effects of host background and route of immunizationVaccine, 2010
- Epitope-based vaccination against pneumonic tularemiaVaccine, 2009
- Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humansVaccine, 2009
- Establishment of lethal inhalational infection with Francisella tularensis (tularaemia) in the common marmoset (Callithrix jacchus)International Journal of Experimental Pathology, 2009
- Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensisVaccine, 2009
- Half- vs Full-Dose Trivalent Inactivated Influenza Vaccine (2004-2005)Archives of internal medicine (1960), 2008
- Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibodyVaccine, 2008
- An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strainVaccine, 2008
- Francisella tularensis LVS grown in macrophages has reduced ability to stimulate the secretion of inflammatory cytokines by macrophages in vitroMicrobial Pathogenesis, 2006